Goodwin Guides Repertoire Immune Medicines on a Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases for $85 Million Upfront, Up to $1.84 Billion in Milestones, and Potential Tiered Royalties
January 30, 2026
January 30, 2026
BOSTON, Massachusetts, Jan. 30 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:
* * *
Goodwin Guides Repertoire Immune Medicines on a Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases for $85 Million Upfront, Up to $1.84 Billion in Milestones, and Potential Tiered Royalties
*
The Life Sciences team guided Repertoire Immune Medicines on entering a strategic collaboration . . .
* * *
Goodwin Guides Repertoire Immune Medicines on a Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases for $85 Million Upfront, Up to $1.84 Billion in Milestones, and Potential Tiered Royalties
*
The Life Sciences team guided Repertoire Immune Medicines on entering a strategic collaboration . . .
